ArticleFrontiers in oncology2013
Opportunities and challenges for successful use of bevacizumab in pediatrics.
Article in Frontiers in oncology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 13 citations in OpenAlex.
- Investigation of Monoclonal Antibody Pharmacokinetics in Pediatric Population and Characterization Using a Platform PBPK Model.The AAPS journal · 2026Article
- Breaking the barrier: a guidelines-based review of antiangiogenesis drug resistance in pediatric cancer therapy.Clinical and experimental pediatrics · 2025Article
- Bevacizumab in Pediatric Neuro-Oncology.Current oncology (Toronto, Ont.) · 2025Review
- Palliative care for children with central nervous system tumors: results of a Spanish multicenter study.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024Article
- Systemic bevacizumab for pediatric patients with aggressive recurrent respiratory papillomatosis: One single-center experience of eight patients.Laryngoscope investigative otolaryngology · 2023Article
- Targeted treatment of solid tumors in pediatric precision oncology.Frontiers in oncology · 2023Review
- Systemic Bevacizumab for Severe Recurrent Respiratory Papillomatosis.Case reports in oncological medicine · 2022Article
- Review
- The Actions of IGF-1 in the Growth Plate and Its Role in Postnatal Bone Elongation.Current osteoporosis reports · 2020Review
- Vascular stenosis in a child with visual pathway glioma treated with bevacizumab: a case report and review of literature.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Bevacizumab (Avastin) has rapidly gained status as a broadly active agent for malignancies of several different histologies in adults. This activity has spawned a range of uses in pediatrics for both oncologic and non-oncologic indications. Early analyses indicate that pediatric cancers exhibit a spectrum of responses to bevacizumab that suggest its activity may be more limited than in adult oncology. Most exciting, is that for low-grade tumors that threaten vision and hearing, there is not only evidence for objective tumor response but for recovery of lost function as well. In addition to oncological indications, there is a range of uses for non-oncologic disease for which bevacizumab has clear activity. Finally, a number of mechanisms have been identified as contributing to bevacizumab resistance in cancer. Elucidating these mechanisms will guide the development of future clinical trials of bevacizumab in pediatric oncology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.